Endogenous CD4+ T cells recognize neoantigens in lung cancer patients including KRAS and ERBB2.. Endogenous CD4+ T cells recognize neoantigens in lung cancer patients including KRAS and ERBB2.

Neoantigen-specific T cell responses were characterized in 4 patients with non-small cell lung cancer. Candidate neoantigens were identified by sequencing tumor and normal DNA from each patient, and ranking single nucleotide variants by expression. Multiple T cell responses were isolated, and in two patients with lung adenocarcinoma, CD4+ T cell responses to recurrent oncogenic mutations in KRAS and Her2 were identified.